Esperion

Quote
This is definitely a sell the rumor buy the news story. The outcomes data will have a profound impact on our history and our legacy as we continue forward in our quest to overcome cardiovascular disease. Our story and core value proposition remains intact, and I look forward to seeing CVD become the number 2 or 3 cause of death in the foreseeable future. We will be able to provide the necessary support and resources for our patients and our providers. The community is counting on us to deliver the best possible service and solutions to overcome CVD. Press on and prevail!
 




The community looks upon on you as a side show attraction at the state fair. Complete imcompetents trying to peddle a below average drug in a crowded selling space. This was a disaster according in to investment community. Sheldon needs to be shown the door quickly . The stock has dropped 80% in his tenure.
 




Make no mistake. This outcome wasn't what Esperion was looking for despite some of the ridiculous posts I've read here. Overwhelming all finance articles on this outcome painted a negative picture for Esperion. The debt load ratio is out of control. Esperion is banking again on one off those 300 million dollar deals based on guidelines. Esperion does about 15 million a quarter now. Even if it bumped up to 30 million a quarter it's still not going to be too long to turn a profit. There's smarter people on Wall St than sit on Esperions Board of Directors.
 




Tough day for buy a pack. Just look at XPi, so unless you were the lucky recipient of a buyout today you didn’t make much money in this space. The value proposition remain strong. Our business is really just starting to get going, and the future is very bright, based upon the newest guidelines, and our ability to help deliver goals to patients and providers. Long is a great way to go. Doubting Thomas’s are going to get ratted out soon.
 




So now it's Doubting Thomas . Really?. What a foolish immature statement about a complete collapse of a company. We know your on the Esperion payroll dipshit. Just keep up the stupid entertaining posts as there good for a laugh. Just do what you do best..... keep losing money.
 




anonymous said:
Tough day for buy a pack. Just look at XPi, so unless you were the lucky recipient of a buyout today you didn’t make much money in this space. The value proposition remain strong. Our business is really just starting to get going, and the future is very bright, based upon the newest guidelines, and our ability to help deliver goals to patients and providers. Long is a great way to go. Doubting Thomas’s are going to get ratted out soon.
Click to expand...
I know you’re being a goof. But seriously what guideline? Those paid for European lipid guys even reinforced statin exetimibe as first and second line. I don’t see any bright days ahead. Sheldon will continue his blame game. Probably now blaming bill sassiela. There’s no one left to blame
 












anonymous said:
Tough day for buy a pack. Just look at XPi, so unless you were the lucky recipient of a buyout today you didn’t make much money in this space. The value proposition remain strong. Our business is really just starting to get going, and the future is very bright, based upon the newest guidelines, and our ability to help deliver goals to patients and providers. Long is a great way to go. Doubting Thomas’s are going to get ratted out soon.
Click to expand...

What a bunch of nonsense.
The money burn continues.
When will this bad investment end?
 




The after hour trading on ESPR is showing down 61% taking the stock down to the $1.00 range. This is horrific. It's all coming apart at the seams and there's no way to fix this. This could be the week where it all comes crashing down. The money burn can't go on.
 




Well, it’s been another tough day for a high tech biosciences in the market, so many great companies have gotten trashed in the most recent downturn. True investors know when the opportunity is ripe and they know how to pull the trigger. The opportunity going forward is almost unlimited, we will define our destiny through our actions.
 




Dumbass you better pull the trigger now to get before its gets down under a $1.00. Get your hand out of your pants and hit that sell button. Don't be a chump. Anyone with half a brain for out of this stock when it dropped from $78.00 down into $30.00 range. Mr Optomistic hasn't been right on one single thing. Penny stock is next. What a slaughter the next few days will be.
 




anonymous said:
Well, it’s been another tough day for a high tech biosciences in the market, so many great companies have gotten trashed in the most recent downturn. True investors know when the opportunity is ripe and they know how to pull the trigger. The opportunity going forward is almost unlimited, we will define our destiny through our actions.
Click to expand...

This person is delusional. Yes. Pull the trigger ! Get out of this dumpster fire!
 








GlobeNewswireMarch 08, 2023

- International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance -


- Following the "Lower Is Better For Longer" Approach to Lipid Management, the Recently Published Paper Provides Evidence-Based Guidance on Using Bempedoic Acid in Atherosclerotic Cardiovascular Disease (ASCVD), Heterozygous Familial Hypercholesterolemia (HeFH) and Statin Intolerance -

- Based on This Guidance, Bempedoic Acid, Available as NEXLETOL(R) or in Combination with Ezetimibe as NEXLIZET(R) is Cited as a "Rational Choices in Patient-Centered Care of Specific Groups of Primary Prevention Patients" -

We will prevail!
 




In your dreams Ann Arbor lackey!. Stock really busting out at $1.77. Stock in danger of being downgraded off of NYSE and sent to NASDAQ if there lucky or to penny stock land. Fantastic job with the data and roll out.
 
















What a bloodbath this week. We're not going to make it. This has gone exactly as we thought. This goes all the way back to the Scrientific Hiring Process that was full of deceit and thievery. This has all come back to haunt Esperion. We new this was envietable. Total classic screw up from day one. The winners are the people who didn't get hired at the cattle call interviews. And now we've watched stock drop from $78.00 to $1.00 and change. Debacle!
 




Top Bottom
Back
Quote